Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Actavis_(2016)
Barr_Pharmaceuticals_(2008) Ratiopharm_(2010) Cephalon_(2011) |
| gptkbp:CEO |
Kåre Schultz
|
| gptkbp:employees |
over 40,000
|
| gptkbp:founded |
1901
|
| gptkbp:founder |
Salomon,_A._A.
|
| gptkbp:global_presence |
over 60 countries
|
| gptkbp:headquarters |
Petah_Tikva,_Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teva Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
gptkb:Asia
gptkb:Latin_America gptkb:North_America Europe |
| gptkbp:partnerships |
Mylan_(2016_merger)
|
| gptkbp:products |
generic drugs
specialty medicines |
| gptkbp:researchAndDevelopment |
focus on oncology
focus on CNS disorders focus on respiratory diseases |
| gptkbp:revenue |
$16.7 billion (2020)
|
| gptkbp:stockExchange |
gptkb:NYSE
gptkb:TEVA |
| gptkbp:sustainability_initiatives |
governance
social responsibility environmental responsibility |